PT-141 is unlike any other medication sold! This new sexual dysfunction prescription is brain based. It creates a reaction in most women and men that can only be described as miraculous.
Product name: PT-141 10mg
Alias: Bremelanotide, PT141,PT-141; Brmelanotide; PT141
CAS: 32780-32-8
MF: C50H69N15O10
MW: 1040.17736
Water Content(Karl Fischer): ≤ 5.0%
Acetate Content(by HPLC): ≤ 15.0%
Amino Acid Composition: ± 10% of theoretical
Purity(by HPLC): ≥ 97.0%
Single Impurity(by HPLC): ≤ 1.0%
Peptide Content(by %N): ≥ 80%
Assay(By Anhydrous, Acetic Acid-free): 95.0~105.0%
Bacterial Endotoxins: ≤ 5EU/mg
Appearance: Freeze-dried powder
For example, one clinical trial investigated the properties of PT-141 between 0 mg (placebo) to 10 mg. The route of administration in this study was intranasal (through the nose).
The LOVER Protocol by Maximus contains PT-141 at a dose of 2000 mcg. Crucially, it also contains tadalafil 5 mg. This allows PT-141 to work synergistically with tadalafil to help you develop and maintain erections.
The LOVER Protocol also differs from typically available PT-141 in that it is packaged in the form of a tablet. It is orally dissolved and fast-acting. This means no nasty injections that can give you swelling or bruising.
In addition, the LOVER Protocol is meant to promote sexual health in general. This means that it is not to be taken only before a sexual encounter, but on a regular basis.
The LOVER Protocol by Maximus contains PT-141 2000 mcg and tadalafil 5 mg. It is intended to boost your sexual health and performance for the immediate and longterm.
To ensure the safe and effective use of PT-141, it is important to follow the recommended dosage guidelines. Let's explore the recommended PT-141 dosage.
Bremelanotide (PT-141) was developed from the peptide hormone Melanotan II. In initial testing, Melanotan II induced darkening of skin pigment, but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects. Further testing in animals showed Bremelanotide to induce lordosis (a sexual mating behavior) and subsequently tested for its effect in humans. Although, most of the research has been targeted to women with female sexual dysfunction an it is effective medication in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system. It is estimated that 43% of women (30 million is the US) suffer from sexual dysfunction and 30 million men suffer from ED, with incidence increasing 2-3 fold between ages 40-70. Bremelanotide currently has no contraindications and is 80% effective in men don't respond to Viagra or Cialis. For women, it causes a 50% increase in sexually satisfying experiences.
